title: Increased cardiotoxicity of sorafenib in sunitinib-pretreated patients with metastatic renal cell carcinoma.
authors.forename: M
authors.initials: M
authors.lastname: Mego
authors.forename: M
authors.initials: M
authors.lastname: Reckova
authors.forename: J
authors.initials: J
authors.lastname: Obertova
authors.forename: Z
authors.initials: Z
authors.lastname: Sycova-Mila
authors.forename: K
authors.initials: K
authors.lastname: Brozmanova
authors.forename: J
authors.initials: J
authors.lastname: Mardiak
mesh_terms: D000368:Aged; D001281:Atrial Fibrillation / Q000139:chemically induced / Q000503:physiopathology; D001557:Benzenesulfonates / Q000009:adverse effects* / Q000627:therapeutic use; D002292:Carcinoma, Renal Cell / Q000188:drug therapy* / Q000473:pathology / Q000556:secondary*; D002318:Cardiovascular Diseases / Q000139:chemically induced* / Q000503:physiopathology; D002637:Chest Pain / Q000139:chemically induced / Q000503:physiopathology; D004347:Drug Interactions; D005500:Follow-Up Studies; D006801:Humans; D007211:Indoles / Q000009:adverse effects* / Q000627:therapeutic use; D007680:Kidney Neoplasms / Q000188:drug therapy* / Q000473:pathology; D008875:Middle Aged; D017202:Myocardial Ischemia / Q000139:chemically induced / Q000503:physiopathology; D009361:Neoplasm Invasiveness / Q000473:pathology; D009367:Neoplasm Staging; D009536:Niacinamide / Q000031:analogs & derivatives; D010671:Phenylurea Compounds; D011725:Pyridines / Q000009:adverse effects* / Q000627:therapeutic use; D011758:Pyrroles / Q000009:adverse effects* / Q000627:therapeutic use; D018570:Risk Assessment; D012494:Sampling Studies; D012720:Severity of Illness Index; D000077157:Sorafenib; D000077210:Sunitinib
chemical_list: D001557:Benzenesulfonates; D007211:Indoles; D010671:Phenylurea Compounds; D011725:Pyridines; D011758:Pyrroles; D009536:Niacinamide; D000077157:Sorafenib; D000077210:Sunitinib